Recalls & Warnings December 08, 2017 Limbrel Capsules for Osteoarthritis Linked With Potentially Life-Threatening Health Risk, FDA Warns On December 4, 2017, the FDA urged consumers not to take Limbrel (Primus Pharmaceuticals), a capsule marketed to manage the metabolic processes associated with osteoarthritis, because it has been associated with serious adverse events, including drug-induced liver injury and a lung
Do not include legal advice, vendor branding, product packaging, buying language, injection instructions, or claims that unapproved products are safe or effective
Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ
This appears to be dose-dependent, with moderate doses enhancing sleep quality while excessive doses may paradoxically impair deep sleep architecture
In addition, specific inhibition of TKTL1 mRNA has been shown to inhibit cancer cell proliferation in functional studies